Trial Profile
A multicenter, open-label extension study of high-risk hyperlipidemic patients treated with an atorvastatin starting dose adapted to their baseline LDL-C [low density lipoprotein cholesterol] level
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Atorvastatin (Primary)
- Indications Hyperlipidaemia
- Focus Therapeutic Use
- Sponsors Pfizer
- 14 Apr 2008 New trial record.